Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
2017 · New England Journal of Medicine · 2,174 citations
https://doi.org/10.1056/nejmoa1709030
H
Helen Gogas
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
601
Papers
34.2K
Citations
74
h-index
280
i10-index
Helen Gogas is an academic researcher from Laiko General Hospital of Athens. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Melanoma and MAPK Pathways & CAR-T cell therapy research. The author has an h-index of 74, co-authored 511 publications.
ORCID: 0000-0002-0451-2885Papers by this author
worksCombined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
2014 · New England Journal of Medicine · 1,825 citations
https://doi.org/10.1056/nejmoa1406037
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
2019 · New England Journal of Medicine · 1,316 citations
https://doi.org/10.1056/nejmoa1904059
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
2019 · Nature Medicine · 1,066 citations
https://doi.org/10.1038/s41591-019-0654-5
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
2022 · Journal of Clinical Oncology · 249 citations
https://doi.org/10.1200/jco.22.00343
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
2020 · Nature Genetics · 230 citations
https://doi.org/10.1038/s41588-020-0611-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat